10th Congress of International Society of Systemic Auto-Inflammatory Diseases (ISSAID)

Table 1 (abstract P2084). Clinical characteristics of 6 girls and 1 boy with recurrent pericarditis and complete response to anakinra

	Pacient 1	Pacient 2	Pacient 3	Pacient 4	Pacient 5	Pacient 6	Pacient 7
Age at onset (years)	9	11	3	12	15	17	1.2
Time from onset to first ANK use	9	24	12	24	2	2	6
Former therapies	Ibuprofene Colchicine Prednisone	Ibuprofene Dexametasone Colchicine	Ibuprofene Prednisone Colchicine	Ibuprofene Prednisone Colchicine	Ibuprofene Prednisone Colchicine	Ibuprofene Prednisone Colchicine	Indometacine Colchicine Prednisolone
Symptoms associated to pericarditis*	Fever Asthenia Pleuritis Peritonitis	Fever Asthenia Skin rash Pleuritis	Fever Abdominal pain	Pachypleuritis	Fever Asthenia	Febricula Pleuritis	Hepatomegaly
CRP (mg/L)*	104	250	162	350	56	150	16
Related disease	No	SoJIA and MAS	No	FMF (mutations M694l and R202Q)	No	Renal trasplantation due to vasculitis	No
CRP (mg/L)**	0.54	0.8	1.63	0.59	2.43	48	Not done yet
Number offlares after starting ANK	0	1 flare, 30 days after ANK withdrawal	0	1 flare, 35 days after voluntarily stopping ANK	0	0	0
Current treatment	None (ANK withdrawn: september 2015)	ANK 100 mg /day	ANK 75 mg every 72 hours	ANK 100 mg/day	ANK 75 mg every 72 hours	ANK 100 mg/day	ANK 50 mg/day

*Maximum values during a typical flare
**First laboratory examinations performed after starting ANK
(ANK: Anakinra. CRP: C-Reactive Protein. SoJIA: Systemic onset Juvenile Idiopathic Arthritis. MAS: Macrophage Activation Syndrome. FMF: Familial Mediterranean Fever)

ISSN: 1546-0096